Jeffrey Cleland Net Worth

Jeffrey Cleland biography

Dr. Jeffrey L. Cleland Ph.D. serves as Independent Director of the Company. He has served as a member of our Board of Directors since July 2019. Dr. Cleland is the co-founder, chairman, chief executive officer and president of Ashvattha Therapeutics, Inc., and co-founder and executive chairman of Orpheris, Inc., a wholly owned subsidiary of Ashvattha, a position he has held since July 2015. He currently serves as a director of ImmunSys, Inc., and Zylem, Inc. He previously served as the chief executive officer, president and director of Graybug Vision, Inc. from May 2016 to September 2018, and as interim chief executive officer of GrayBug, Inc. from May 2015 to May 2016. Dr. Cleland co-founded Versartis, Inc. in 2008 and served as its chief executive officer and president from May 2009 to May 2015. Dr. Cleland also founded and served as a chief executive officer and director for Diartis Pharmaceuticals, Inc. from December 2010 to March 2013. Dr. Cleland also acted as an adjunct assistant professor at University of the Pacific, University of Kansas and University of Colorado. He holds a BS in Chemical Engineering from the University of California, Davis and a Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology. Our Board believes that Dr. Cleland’s experience in drug development and as a director and executive at various biopharmaceutical companies qualify him to serve on the Board.

What is the salary of Jeffrey Cleland?

As the Independent Director of Exicure Inc, the total compensation of Jeffrey Cleland at Exicure Inc is $88,922. There are 10 executives at Exicure Inc getting paid more, with David Giljohann having the highest compensation of $785,462.

How old is Jeffrey Cleland?

Jeffrey Cleland is 55, he's been the Independent Director of Exicure Inc since 2019. There are 4 older and 7 younger executives at Exicure Inc. The oldest executive at Exicure Inc is David Walt, 67, who is the Independent Director.

What's Jeffrey Cleland's mailing address?

Jeffrey's mailing address filed with the SEC is C/O EXICURE, INC., 2430 N. HALSTED STREET, CHICAGO, IL, 60614.

Insiders trading at Exicure Inc

Over the last 6 years, insiders at Exicure Inc have traded over $4,850,172 worth of Exicure Inc stock and bought 7,217,940 units worth $10,705,021 . The most active insiders traders include Timothy P Walbert, Co., Ltd. Dgp, and Usa, Inc. Cbi. On average, Exicure Inc executives and independent directors trade stock every 90 days with the average trade being worth of $928,360. The most recent stock trade was executed by Co., Ltd. Dgp on 29 February 2024, trading 3,400,000 units of XCUR stock currently worth $4,488,000.

What does Exicure Inc do?

exicure, formerly aurasense therapeutics, is developing a new class of immunomodulatory and gene silencing drugs against validated targets. our 3-dimensional, spherical nucleic acid (sna™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. our lead programs address diseases from inflammatory disorders to oncology. sna constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. sna constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. moreover, snas can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease.

Exicure Inc executives and stock owners

Exicure Inc executives and other stock owners filed with the SEC include:

• David Giljohann,
  Chief Executive Officer, Interim Principal Financial Officer, Corporate Secretary, Director
• Matthias Schroff,
  Chief Operating Officer
• Dr. Douglas E. Feltner,
  Chief Medical Officer
• Chad Mirkin,
  Director
• Bali Muralidhar,
  Independent Director
• Bosun Hau,
  Independent Director
• Jay Venkatesan,
  Independent Director
• Helen Kim,
  Independent Director
• Timothy Walbert,
  Independent Chairman of the Board
• David Walt,
  Independent Director
• Jeffrey Cleland,
  Independent Director
• Karen Sharma,
  Investor Relations
• Bart Anderson,
  Sr. Director of R&D
• Dr. Emil M. deGoma M.D.,
  VP of Clinical Devel.
• Weston Daniel,
  VP of Translational Research
• Sarah Longoria,
  VP of HR
• Christoph Jaeker,
  VP of Corp. Devel. & Strategy
• Elias D. Papadimas,
  Chief Accounting Officer
• Brian C. Bock,
  Chief Financial Officer
• Elizabeth A. Garofalo,
  Director
• Andy Sassine,
  Director
• Llc Aurasense,
  10% owner
• Douglas E. Feltner,
  Chief Medical Officer
• James R Sulat,
  Director
• Colby Shad Thaxton,
  Director
• David S Snyder,
  Chief Financial Officer
• Frontier, Llcgates William ...,
  
• Brian Bock,
  Chief Financial Officer
• Co., Ltd. Dgp,
  
• Elias D. Papadimas,
  Chief Financial Officer
• Sarah Longoria,
  Chief HR & Compliance Officer
• Usa, Inc. Cbi,
  
• Jiyoung Hwang,
  Director
• Josh Miller,
  Chief Accounting Officer